CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellino and Matricelf (TASE: MTLF) announced today a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using ...
TEL AVIV, Israel, Feb. 7, 2022 /PRNewswire/ -- Matricelf (TASE:MTLF) announced today that scientists from Sagol Center for Regenerative Biotechnology at Tel Aviv University have engineered 3D spinal ...
Matricelf Ltd. is a biotechnology company, which engages in research and development of a platform for autologous matrix and cell implants in the field of regenerative medicine and tissue engineering.
PHOENIX and NESS ZIONA, Israel, Feb. 26, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company advancing personalized curative treatments for spinal cord injury, announced ...
NESS ZIONA, Israel, March 3, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced that it has signed a ...
Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies for spinal cord injury, today issued a shareholder update summarizing its 2025 achievements and ...
Cellino successfully manufactures and delivers autologous iPSC lines from four donors to Matricelf for groundbreaking neural tissue engineering CAMBRIDGE, Mass., March 11, 2025--(BUSINESS ...
Matricelf Ltd. Annual stock financials by MarketWatch. View the latest MTRLF financial statements, income statements and financial ratios.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results